NVAX
Price
$5.39
Change
+$0.45 (+9.11%)
Updated
Mar 1, 6:59 PM EST
66 days until earnings call
SAVA
Price
$23.00
Change
+$0.02 (+0.09%)
Updated
Mar 1, 6:59 PM EST
58 days until earnings call
Ad is loading...

NVAX vs SAVA ᐉ Comparison: Which is Better to Invest?

Header iconNVAX vs SAVA Comparison
Open Charts NVAX vs SAVABanner chart's image
Novavax
Price$5.39
Change+$0.45 (+9.11%)
Volume$9M
CapitalizationN/A
Cassava Sciences
Price$23.00
Change+$0.02 (+0.09%)
Volume$232.19K
CapitalizationN/A
View a ticker or compare two or three
NVAX vs SAVA Comparison Chart

Loading...

NVAXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
SAVADaily Signal changed days agoGain/Loss if shorted
 
Show more...
VS
NVAX vs. SAVA commentary
Mar 02, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is NVAX is a StrongBuy and SAVA is a Hold.

COMPARISON
Comparison
Mar 02, 2024
Stock price -- (NVAX: $5.39 vs. SAVA: $23.00)
Brand notoriety: NVAX: Notable vs. SAVA: Not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: NVAX: 101% vs. SAVA: 35%
Market capitalization -- NVAX: $583.85M vs. SAVA: $971.45M
NVAX [@Biotechnology] is valued at $583.85M. SAVA’s [@Biotechnology] market capitalization is $971.45M. The market cap for tickers in the [@Biotechnology] industry ranges from $541.24B to $0. The average market capitalization across the [@Biotechnology] industry is $2.59B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

NVAX’s FA Score shows that 0 FA rating(s) are green whileSAVA’s FA Score has 0 green FA rating(s).

  • NVAX’s FA Score: 0 green, 5 red.
  • SAVA’s FA Score: 0 green, 5 red.
According to our system of comparison, SAVA is a better buy in the long-term than NVAX.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

NVAX’s TA Score shows that 5 TA indicator(s) are bullish while SAVA’s TA Score has 2 bullish TA indicator(s).

  • NVAX’s TA Score: 5 bullish, 5 bearish.
  • SAVA’s TA Score: 2 bullish, 6 bearish.
According to our system of comparison, NVAX is a better buy in the short-term than SAVA.

Price Growth

NVAX (@Biotechnology) experienced а +1.89% price change this week, while SAVA (@Biotechnology) price change was +4.88% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +7.02%. For the same industry, the average monthly price growth was +20.20%, and the average quarterly price growth was +48.09%.

Reported Earning Dates

NVAX is expected to report earnings on May 07, 2024.

SAVA is expected to report earnings on Apr 29, 2024.

Industries' Descriptions

@Biotechnology (+7.02% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
A.I.dvisor published
a Summary for NVAX with price predictions.
OPEN
A.I.dvisor published
a Summary for SAVA with price predictions.
OPEN
FUNDAMENTALS
Fundamentals
SAVA($971M) has a higher market cap than NVAX($584M). NVAX YTD gains are higher at: 12.292 vs. SAVA (2.177). SAVA has higher annual earnings (EBITDA): -102.54M vs. NVAX (-498.29M). NVAX has more cash in the bank: 651M vs. SAVA (142M). SAVA has less debt than NVAX: SAVA (0) vs NVAX (222M). NVAX has higher revenues than SAVA: NVAX (974M) vs SAVA (0).
NVAXSAVANVAX / SAVA
Capitalization584M971M60%
EBITDA-498.29M-102.54M486%
Gain YTD12.2922.177565%
P/E RatioN/AN/A-
Revenue974M0-
Total Cash651M142M458%
Total Debt222M0-
FUNDAMENTALS RATINGS
NVAX vs SAVA: Fundamental Ratings
NVAX
SAVA
OUTLOOK RATING
1..100
454
VALUATION
overvalued / fair valued / undervalued
1..100
85
Overvalued
55
Fair valued
PROFIT vs RISK RATING
1..100
10075
SMR RATING
1..100
10097
PRICE GROWTH RATING
1..100
5050
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
50n/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

SAVA's Valuation (55) in the Pharmaceuticals Other industry is in the same range as NVAX (85) in the Biotechnology industry. This means that SAVA’s stock grew similarly to NVAX’s over the last 12 months.

SAVA's Profit vs Risk Rating (75) in the Pharmaceuticals Other industry is in the same range as NVAX (100) in the Biotechnology industry. This means that SAVA’s stock grew similarly to NVAX’s over the last 12 months.

SAVA's SMR Rating (97) in the Pharmaceuticals Other industry is in the same range as NVAX (100) in the Biotechnology industry. This means that SAVA’s stock grew similarly to NVAX’s over the last 12 months.

SAVA's Price Growth Rating (50) in the Pharmaceuticals Other industry is in the same range as NVAX (50) in the Biotechnology industry. This means that SAVA’s stock grew similarly to NVAX’s over the last 12 months.

SAVA's P/E Growth Rating (100) in the Pharmaceuticals Other industry is in the same range as NVAX (100) in the Biotechnology industry. This means that SAVA’s stock grew similarly to NVAX’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
NVAXSAVA
RSI
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
Stochastic
ODDS (%)
Bearish Trend 1 day ago
89%
Bullish Trend 1 day ago
90%
Momentum
ODDS (%)
Bullish Trend 1 day ago
80%
Bearish Trend 1 day ago
90%
MACD
ODDS (%)
Bullish Trend 1 day ago
87%
Bearish Trend 1 day ago
87%
TrendWeek
ODDS (%)
Bullish Trend 1 day ago
84%
Bullish Trend 1 day ago
86%
TrendMonth
ODDS (%)
Bullish Trend 1 day ago
87%
Bearish Trend 1 day ago
89%
Advances
ODDS (%)
Bullish Trend 1 day ago
82%
Bullish Trend 16 days ago
85%
Declines
ODDS (%)
Bearish Trend 10 days ago
90%
Bearish Trend 5 days ago
87%
BollingerBands
ODDS (%)
Bearish Trend 1 day ago
90%
N/A
Aroon
ODDS (%)
Bearish Trend 1 day ago
90%
Bearish Trend 1 day ago
86%
View a ticker or compare two or three
Ad is loading...
NVAXDaily Signal changed days agoGain/Loss if shorted
 
Show more...
SAVADaily Signal changed days agoGain/Loss if shorted
 
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
PJRAX7.22N/A
N/A
PGIM Quant Solutions International Eq A
TIQIX25.14N/A
N/A
Touchstone Non-US ESG Equity Y
COAGX40.10N/A
N/A
Caldwell & Orkin - Gator Capital L/S Fd
TEGRX25.72N/A
N/A
Templeton Growth R
FESAX9.81N/A
N/A
First Eagle Small Cap Opportunity A

NVAX and

Correlation & Price change

A.I.dvisor indicates that over the last year, NVAX has been loosely correlated with CRSP. These tickers have moved in lockstep 47% of the time. This A.I.-generated data suggests there is some statistical probability that if NVAX jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NVAX
1D Price
Change %
NVAX100%
+9.66%
CRSP - NVAX
47%
Loosely correlated
-0.58%
THRD - NVAX
42%
Loosely correlated
+1.88%
SYRE - NVAX
38%
Loosely correlated
+8.97%
MRNA - NVAX
37%
Loosely correlated
+3.06%
RCUS - NVAX
35%
Loosely correlated
-0.05%
More

SAVA and

Correlation & Price change

A.I.dvisor indicates that over the last year, SAVA has been loosely correlated with CRSP. These tickers have moved in lockstep 35% of the time. This A.I.-generated data suggests there is some statistical probability that if SAVA jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To SAVA
1D Price
Change %
SAVA100%
N/A
CRSP - SAVA
35%
Loosely correlated
-0.58%
IBRX - SAVA
29%
Poorly correlated
-0.21%
ATXI - SAVA
27%
Poorly correlated
+3.82%
SRNEQ - SAVA
27%
Poorly correlated
N/A
LXRX - SAVA
26%
Poorly correlated
+0.40%
More